Sporadic Creutzfeldt–Jakob disease infected human cerebral organoids retain the original human brain subtype features following transmission to humanized transgenic mice
Acta Neuropathologica Communications volume 11, Article number: 28 (2023)
Human cerebral organoids (COs) are three-dimensional self-organizing cultures of cerebral brain tissue differentiated from induced pluripotent stem cells. We have recently shown that COs are susceptible to infection with different subtypes of Creutzfeldt–Jakob disease (CJD) prions, which in humans cause different manifestations of the disease. The ability to study live human brain tissue infected with different CJD subtypes opens a wide array of possibilities from differentiating mechanisms of cell death and identifying neuronal selective vulnerabilities to testing therapeutics. However, the question remained as to whether the prions generated in the CO model truly represent those in the infecting inoculum. Mouse models expressing human prion protein are commonly used to characterize human prion disease as they reproduce many of the molecular and clinical phenotypes associated with CJD subtypes. We therefore inoculated these mice with COs that had been infected with two CJD subtypes (MV1 and MV2) to see if the original subtype characteristics (referred to as strains once transmitted into a model organism) of the infecting prions were maintained in the COs when compared with the original human brain inocula. We found that disease characteristics caused by the molecular subtype of the disease associated prion protein were similar in mice inoculated with either CO derived material or human brain material, demonstrating that the disease associated prions generated in COs shared strain characteristics with those in humans. As the first and only in vitro model of human neurodegenerative disease that can faithfully reproduce different subtypes of prion disease, these findings support the use of the CO model for investigating human prion diseases and their subtypes.
Prion diseases (PrD) are a family of fatal, neurodegenerative conditions that affect humans and animals. PrDs have three etiologies: hereditary, acquired by infection and sporadic (no known cause), of which the most common form is sporadic Creutzfeldt Jakob Disease (sCJD). Prions are misfolded conformers of the normal cellular prion protein (PrPC). Once formed, disease associated prions (PrPD) can recruit PrPC causing it to also misfold and in this way propagate themselves in an ongoing cycle. sCJD, has several subtypes, as determined by biochemical signatures of the prion protein (PrPD) and the lesions formed within the brain [1,2,3]. The hallmark features of prion diseases include deposits of insoluble, protease resistant prion protein (PrP) isoforms (PrPRes), astrogliosis, and spongiform changes in the brain. However, the different subtypes manifest different symptoms in patients and follow different disease courses. The different symptomology and disease course of sCJD subtypes in humans has been attributed to selective neuronal vulnerability, where certain neuronal subsets are more vulnerable to attack by one sCJD subtype than by others . Understanding neuronal selective vulnerability has been limited by the lack of human neuronal cultures that can propagate different human prion subtypes.
The basis for the different manifestations of the disease, caused by the same protein, is currently unknown but is thought to be encoded in slight structural differences within the PrPD [5,6,7,8]. These subtype dependent structural changes are demonstrated by small shifts in the mobility of PrPRes during electrophoresis and western blotting, for example type 1 or type 2 sCJD . The PrPRes banding pattern can be further characterized by the relative abundance of its three glycoforms, di-, mono- and un-glycosylated, with the mono-glycosylated band being dominant in sCJD brain. Furthermore, a polymorphism at codon 129 of the prion protein gene, encoding for either methionine (M) or valine (V), also influences disease course and susceptibility. Together, the M/V genotype and PrPRes mobility pattern tend to couple with disease course and symptomology and are used to classify the different disease subtypes [1, 3, 9].
We previously sought to develop an in vitro human model of prion disease that could reproduce the subtype phenomena seen in the brain. To this end we generated cerebral organoids (COs) derived from human induced pluripotent stem cells ( and Additional File 1: Figure S1). COs are three-dimensional spheres of human brain tissue containing diverse cerebral cortex cell types and distinct neuronal populations [11, 12]. The COs were able to take up and clear the initial sCJD brain homogenate (BH) inocula then propagate de novo prions templated by the inoculating PrPD (Additional File 1: Figure S1). Brain homogenates from two different sCJD subtypes were used and were classified as, MV1 and MV2 (using the classification system in [3, 9]). The organoids infected with the MV1 subtype showed only a small accumulation of prions, below the detection threshold of western blot, but demonstrated distinct changes in organoid health, more so than with MV2. The organoids infected with the subtype classified as MV2 accumulated prions that were detectible by western blotting and deposits were visualized by immunohistochemistry for prion protein within the organoids. However, the MV2 PrPRes showed a changed electrophoretic profile from that expected: these organoids generated predominantly di-glycosylated PrPRes rather than the expected mono-glycosylated dominant banding (which is characteristic of MV2 sCJD) ([10, 13] and Additional File 1: Figure S1). Di-glycosylated PrPC is the primary glycoform in these organoids, so it is therefore not surprising that the PrPRes deposited in them would be as well. However, since organoids offer many possible advantages over traditional cultures systems for investigating human prion disease [13,14,15], it was important to ascertain how accurately the organoids reproduced the original disease or whether the shift in glycosylation resulted from a tissue culture induced change in the propagating PrPD analogous to a strain adaptation.
Strain adaptations often occur when prions are passaged through new hosts  where cellular differences such as cofactor availability  result in phenotypic change such as altered incubation time and PrPD deposition . For example, sheep scrapie passed through either mice or goats, and then mice, has given rise to multiple strains of rodent adapted scrapie, each with distinct clinical and biochemical manifestations . The gold standard for investigating prion strain phenomenon remains mouse bioassay . Transgenic mice can be made that are susceptible to a wide variety of prion strains and demonstrate remarkable reproducibility of disease phenotype for a given strain . While passaging human prions into human tissue (cerebral organoids) does not necessarily constitute a host difference, the environment within the organoid may differ from an intact human brain. Therefore, to determine whether the prions produced by sCJD infection of organoids retain the features of the original inoculum or result in a strain adaptation, we performed bioassays using tg66 mice overexpressing human PrPC . Our findings demonstrated that the clinical and biochemical properties of the prions propagated in mice following inoculation with sCJD infected organoid homogenates were nearly indistinguishable from those inoculated with the original brain derived inocula. Additionally, the observed maintenance of the original sCJD subtypes after passage through the organoids indicates that organoids propagate prion disease with the attributes of the parent subtype without any apparent strain adaptation.
Tg66 transgenic mice overexpressing human PrPC were used for this study. These mice have been shown to be susceptible to prion disease by infection with MV1 and 2 sCJD prions, with distinct disease courses and biochemistry apparent with the different inocula . Generation of these mice was described previously . Tg66 mice were originally made by Richard Rubenstein and provided to RML by Robert Rohwer. Tg66 mice are on an FVB/N genetic background and are homozygous for a transgene that encodes human prion protein M129. Tg66 mice overexpress human PrPC at 8–16-fold levels higher than normal physiologic levels and have been shown to be susceptible to vCJD, sCJD and mouse-adapted 22L scrapie [22, 24]. Tg66 mice do not express any normal mouse PrPC.
Mouse inoculations and observations
Homogenates for inoculation were diluted from existing 10–20% whole organoid, human brain or mouse brain homogenates (Additional File 1: Figure S1). Briefly, aliquots of 10–20% homogenates in sterile phosphate buffered saline (PBS, pH 7.4) were sonicated for 1 min at a 60% amplitude setting. Following sonication, homogenates were further diluted to a 1% w/v concentration in phosphate buffered balanced saline supplemented with 2% fetal bovine serum. Mice were anesthetized with isoflurane and inoculated in the left brain hemisphere with 30 µl of 1% tissue homogenate. For the first passage experiments, 8–10 mice were inoculated for each experimental (homogenate) group, including MV1 or MV2 brain homogenate (MV-BH) or MV1 or MV2 infected CO homogenate (MV-OH). The second passage experiments included 8–12 mice per group inoculated with brain homogenate from mice inoculated with either BH or OH (MV-BH (ms) or MV-OH (ms)).
Post-inoculation, all mice were observed once daily by animal care staff and 3–5 times weekly by investigators for assessment of overall health and observation for signs consistent with prion infection. Mice inoculated with first passage MV1-BH, second passage MV1-BH (ms) or MV1-OH (ms) developed clinical signs including nesting deficiencies, gait abnormalities, weight loss, despondence, respiratory difficulty and tail wounding. The typical MV1 disease course was progressive and lasted 3–4 weeks. Mice were considered “clinical” and euthanized when they were nearing a moribund condition. Mice that were euthanized early or found dead due to non-TSE related reasons were excluded from the total clinical numbers. However, some tissues from excluded animals were still used for other analyses. Mice inoculated with first passage MV2-BH or OH and second passage MV2-BH or OH (ms) had a longer incubation period and the duration of clinical signs was much longer than MV1-infected mice, ranging 6–13 weeks. Common clinical signs in MV2 infected mice included weight loss, urinary bladder distention and incontinence, kyphosis, gait abnormalities, poor coat quality, crusted blood in the nares, progressive lethargy and somnolence.
Real-time quaking-induced conversion (RT-QuIC) assay
RT-QuIC assays to measure prion seeding activity were performed as previously described [25, 26]. Briefly, 10% (w/v) pre-cleared BHs were serially diluted by 10 folds in 0.1% sodium dodecyl sulfate (SDS)/PBS/N2. Samples were tested in quadruplicate wells of a 384 well plate (Nunc). One µL of sample dilution was added to each well along with 49 µL of reaction mix (final concentrations of: 10 mM phosphate buffer [pH 7.4], 300 mM NaCl, 0.1 mg/mL hamster recombinant PrP 90–231, 10 μM thioflavin T (ThT), 1 mM ethylenediaminetetraacetic acid tetrasodium salt and 0.002% (w/v) SDS). Plates were sealed and incubated in a FLUOstar Omega plate reader (BMG) at 50 °C for 30 h with cycles of 60 s of shaking (700 rpm, double orbital) and 60 s of rest. ThT fluorescence was measured every 45 min (excitation, 450 ± 10 nm; emission, 480 ± 10 nm [bottom read]). As described previously, individual replicate wells were considered positive for seeding activity when the fluorescence value exceeded a threshold of 10% of the maximum value from any individual reaction well in the experiment within the 50 h time cutoff [10, 27, 28]. A sample was considered positive if greater than 25% of the reaction wells showed positive seeding activity. Data was plotted using GraphPad Prism 9.
Brain homogenates in PBS containing 1% (v/v) sarkosyl were digested with 50 ug/ml PK at 37 °C for 1 h before boiling for 5 min in 1 × sample buffer (Invitrogen) containing 6% (v/v) 2-Mecaptoethanol. Samples were resolved in Bolt 4–12% Bis–Tris gels (Invitrogen) and transferred to PVDF membrane (Millipore). Membranes were blocked with EveryBlot Blocking Buffer (Biorad) for 10 min and incubated in anti-PrP 3F4 antibody (Millipore) at 1:10,000 dilution overnight. The protein bands were visualized using ECL Select (Amersham) and imaged using the iBright imaging system (Invitrogen).
Immunohistochemistry, histology and lesion profiling
Brain fixation, paraffin embedding, H&E staining and immunohistochemistry for prion protein (biotinylated-3F4) were carried out as described previously . Histopathology slides were analyzed by an observer blinded to the animal inoculation groups. Lesion profiling for spongiform pathology was completed on all available mice, as indicated in Tables 2 and 4. Nine brain regions (frontal cortex, hippocampus, striatum, thalamus, hypothalamus, colliculi, midbrain, pons/medulla, and cerebellum) were scored for spongiosis as follows: 0, no vacuoles; 1, few vacuoles widely and unevenly distributed; 2, few vacuoles evenly distributed; 3, moderate numbers of vacuoles evenly distributed; and 4, many vacuoles with some confluences. Lesion scores were graphed and presented using GraphPad prism.
Statistical analysis, as indicated in figure legends, was carried out in GraphPad Prism. Lesion scores were compared by Mann–Whitney U test (p < 0.05).
sCJD prions from infected organoids transmit to mice.
To investigate how true the prions propagated in the COs described in Groveman et al.  were to those from the original brain derived prions, homogenate from two of the organoids (MV genotype at codon 129) per subtype (reported in the original study as MV1-B, MV1-E, MV2-B, and MV2-D) and homogenates from the original MV-1 or -2 sCJD brains were inoculated into tg66 huPrP 129MM mice. The inocula and their prion titers (logSD50/ mg by RT-QuIC analysis) are shown in Table 1. Mice inoculated with sCJD brain homogenate succumbed to prion disease with a mean survival of 176 ± 4 days and 420 ± 23 days for the MV1-BH and MV2-BH inoculated mice, respectively (Fig. 1a, Table 2). Mice infected with the MV2 organoid homogenates (MV2-OH) all developed prion disease (mean survival of 501 ± 85 with MV2-OH (B) inoculum and 536 ± 56 with MV2-OH (D) inoculum) (Fig. 1a, Table 2) but showed a delay compared to the MV2-BH infected mice. While no MV1 organoid homogenate inoculated mice (MV1-OH) showed clear clinical signs of prion disease out to 700 dpi, two were found dead (296 and 302 dpi) and one was euthanized for other reasons (609 dpi) and their brain tissue found to be RT-QuIC positive, with PrP deposition detected by western blot and, in the one case where available, positive for immunohistochemical (IHC) hallmarks of prion disease (Fig. 1b–d, Fig. 2, Table 2). Although IHC staining was only positive in one MV1-OH infected mouse, cursory examination revealed lesion profiling very similar to the MV1-BH infected mice (Fig. 1d: MV1-OH*, Additional File 2: Figure S2). Similarly, the pattern of PrP deposition in the brain of this mouse followed that of the MV1-BH infections (Fig. 2) where deposition was primarily localized to the thalamus and midbrain. PrPD staining was diffuse-synaptic in the thalamus and with prominent perineuronal granular staining in the midbrain. The remaining MV1-OH infected mice showed very few lesions, an observation similar to those in age-matched mice inoculated with NBH-OH (Fig. 1d, Additional File 2: Figure S2, Additional File 4: Table S1A). Analysis of the MV2-OH infection lesion profiles showed greater similarity with the MV2-BH than the MV1-BH inoculated mice (Fig. 1d, Additional File 2: Figure S2, Additional File 4: Table S1A). Additionally, the pattern of PrP deposition in the MV2-OH mice closely followed that of the MV2-BH infected mice (Fig. 2) where large PrP positive plaques were observed closely associated with the corpus callosum. In the samples positive by western blot, banding patterns similar to the original inocula  were observed for both BH and OH infected animals, with the MV1 samples migrating more slowly through the gels (Fig. 1c).
Sub-passaged prions from organoid homogenate inoculated mice cause disease with characteristics of the original human brain subtype inocula
Since the lower prion seeding titers of the organoid inocula (Table 1) likely account for the differences in attack rates, incubation periods, RT-QuIC, western blot and/or IHC positivity, we performed a second passage using western blot and IHC positive brains from the OH and BH infected mice. The sub-passaged inocula and their prion titers (logSD50/mg by RT-QuIC analysis) are shown in Table 3. In this subpassage all infected mice succumbed to prion disease and the survival times clearly grouped as type 1 or type 2 regardless of whether the original inoculum had come from brain homogenate (MV-BH (ms)) or organoids (MV-OH (ms)) (“ms” indicates passage through mice; Fig. 3a). In the first passage, the MV2-OH mice had a longer survival time than the MV2-BH mice (Fig. 2a); however, in the second passage the MV2-OH (ms) mice had a slightly shorter survival time than the MV2-BH (ms) mice (Fig. 3a). This subtle difference can likely be attributed to the differences in prion titer of the inoculum used at each passage (Table 1 and 3). All tested brains were positive by RT-QuIC (Fig. 3b, Table 4) and were positive for PrPRes by western blotting (Fig. 3c, Table 4). The banding profile of the western blots also indicated that the mobility associated with the different subtypes had been preserved. IHC analyses showed clear differences between the MV1 and MV2 infections with only diffuse-synaptic and perineuronal granular deposition of PrP in the MV1 infections compared with large PrPD plaques in the corpus callosum, smaller widespread plaques, coarse granular staining and a lesser amount of diffuse PrPD in the MV2 infections (Fig. 4). Further examination of the H&E stained brains revealed that, while not perfectly overlapping, MV-OH (ms) and MV-BH (ms) inocula produced very similar lesion profiles (Fig. 3d and Additional File 3: Figure S3, Additional File 1: Table S1B).
Human cerebral organoids offer a powerful model of brain tissue in a dish that can be used to investigate neurodegenerative disorders. Our previous work showed that cerebral organoids could be infected with sCJD prions derived from human brain tissue. However, as organoids represent, but are not actual brain tissue, it was imperative to determine if the prions propagated within them were the original subtype or adaptations. This knowledge is necessary to properly understand the data produced and its potential limitations.
In our initial study we noted a change in the glycosylation pattern of the PrPRes deposited in the organoids which we postulated could be a sign of strain adaptation. However, recent studies on RML  and anchorless RML  prions, which lack a glycophosphatidylinositol anchor and are deficient in N-linked glycans, show nearly identical atomic structures. This suggests that while glycosylation differences may depend on the host environment, the subtype information is encoded in the protein backbone conformation and is not materially affected by the addition of glycans. Indeed, our current data show that despite the shift in glycosylation state the prions generated by infection of the organoids are both infectious when inoculated into mice and maintain their original subtype characteristics. Incubation periods, lesion profiles, patterns of PrPD deposition throughout the brain, and PrPRes electrophoretic mobility profiles all suggest that the organoid propagated prions do not deviate substantially from the brain-derived prions with which they were inoculated. In fact, despite having higher titers of prion seeding activity, the MV2 derived homogenates had longer incubation periods in mice than the MV1 derived homogenates, consistent with the clinical presentation of these subtypes in humans .
The incubation periods of different type 1 and 2 brain homogenates in humanized mice vary in the literature [23, 33,34,35]. This is at least partially due to the mouse strain, which may have different PrPC expression levels, and classification system used to define the subtypes. However, the strain characteristics of these prion subtypes can be propagated with little change upon subpassage, regardless of the 129 polymorphism of the inoculum or mouse . In our work, the brains originally used for inoculation  gave widely divergent, subtype dependent, incubation periods and plaque pathologies in the infected mice, making the subtype differences more apparent. This allowed us to more easily determine that each of the original infecting prions had not been substantially changed by passage through the organoid.
Although the MV1-OH inoculated mice showed an extended incubation period on first passage which was substantially shortened on subpassage to match that of the MV1-BH inoculated mice, we do not attribute this to a strain adaptation. Instead, it is more likely that the prion titer is responsible for the difference in incubation periods . The original MV1-OH inoculum had > 1000-fold less prion seeding activity than the MV1-BH inocula (Table 1). At the endpoints of the first passage (609 for the mouse that was subsequently used for subpassage vs 180 dpi, respectively), the MV1-OH inoculated mouse brain tissue had a prion seeding titer nearly equivalent to the MV1-BH inoculated mouse brain tissue used for subpassage (Table 3). Aside from the incubation period difference, the other disease characteristics in the mouse with subclinical disease closely matched the MV1-BH inoculated mice. Additionally, since the incubation periods in the MV2 inoculated animals closely followed their respective titers as well (Tables 1 and 3), we conclude that the change in incubation period in the MV1-OH mice from first to second passage is likely a result of prion titer and not indicative of a strain adaptation.
There also remains the possibility that, as COs are non-dividing cultures, remnant human brain tissue derived PrPD may still be present from the initial inoculation and be responsible for the infection in mice. Indeed, residual inocula is a critical concern when studying infection in COs. In our initial study ( and Additional File 1: Figure S1), we followed the residual inoculum, as detected by RT-QuIC, and observed the complete disappearance around 25–30 dpi followed by the re-emergence at later time points of RT-QuIC positivity to levels greater than those immediately following inoculation. Since the RT-QuIC assay has been demonstrated to be more sensitive than animal bioassay and able to detect sub-infectious levels of PrPD [28, 38,39,40], the complete loss of RT-QuIC detection of the inocula suggests that, if present, the residual inocula in the organoids would not be sufficient to cause disease in animals, even following subpassage . Instead, this suggests that organoid derived PrPD is responsible for both MV1 and MV2 infections despite the long incubation period and low detection in the first passage MV1-OH inoculated mice. While we don’t yet know if serial subpassages through COs would eventually result in deviation from the original inoculating subtype, or whether inoculation into mice may have helped stabilize the strains [42, 43], we now know that the characteristics of the PrPD generated in the organoid and the resulting infection cause by initial inoculation with a particular subtype are maintained.
The maintenance of the subtype characteristics in the infected organoids is beneficial for investigating prion pathogenesis in different neuronal populations. As previously stated, investigation into how the different subtypes cause different prion disease phenotypes and selectively attack different neuronal subsets has been limited by the lack of a human-derived model in which propagation of different subtypes could be faithfully reproduced. With confidence in the reproduction of the prion subtype features within the organoids, we may be able to address the questions as to why the disease proceeds faster in certain subtypes and begin to mechanistically analyze subtype-dependent pathogenesis. Furthermore, we may be able to extend this investigation to other prion subtypes as well as prions associated with hereditary disease. While ourselves and others have reported no evidence of propagating prions in human iPSC derived organoids and neurons from several hereditary disease-causing mutations [25, 44, 45], other pathological changes have been observed such as tau accumulation  and neuronal network dysfunction . Infection of organoids with hereditary PrP mutations may reveal the different pathways by which these prions produce their own manifestation of prion disease.
A further advantage of the organoid system that benefits from the maintenance of subtype properties is the potential use for screening therapeutics, as we have previously demonstrated . An ideal drug would be effective against all prion disease subtypes, but this is not always the case. Now, with a model that can maintain the sCJD subtype, it may be possible to discern if a potential therapeutic strategy will work across all subtypes or be more effective in one type over another. It should be noted that, like all disease models, organoids are not without their limitations. We have discussed many of these, the impact they have on interpretation of results, and possible improvements to the system previously [13, 15]. However, the closer the system can come to representing genuine human diseases the better the chance we can translate our findings into meaningful interventions.
Protein misfolding diseases are characterized by the aggregation of self-propagating misfolded proteins that spread throughout the nervous system. Structural perturbations of these misfolded proteins give rise to unique strains, each with their own pathological characteristics. Deeper understanding of this strain phenomena can help to gain better insight into the mechanisms of neurodegeneration. Herein we provide evidence that cerebral organoids can be used to faithfully propagate specific strains of prion disease as confirmed by transmission into the gold standard animal bioassay. The original infecting prion appears to be the predominant determinant of the prion propagated within the human cerebral organoids with little if any modification by the organoid environment. As the first in vitro fully human model of neurodegenerative disease that is capable of propagating and transmitting disease while maintaining subtype characteristics, cerebral organoids provide a critical platform for better understating prion-induced neurodegeneration.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
- PrPRes :
Protease resistant PrP
Sporadic Creutzfeldt–Jacob disease
- PrPD :
- PrPC :
CJD (either type 1 or 2) infected BH
CJD (either type 1 or 2) infected OH
- MV-BH (ms):
Mouse BH originally infected with CJD infected BH
- MV-OH (ms):
Mouse BH originally infected with CJD infected OH
Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, Ironside JW, Collinge J (2003) Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain J Neurol 126:1333–1346. https://doi.org/10.1093/brain/awg125
Notari S, Capellari S, Langeveld J, Giese A, Strammiello R, Gambetti P, Kretzschmar HA, Parchi P (2007) A refined method for molecular typing reveals that co-occurrence of PrP(Sc) types in Creutzfeldt-Jakob disease is not the rule. Lab Invest J Tech Methods Pathol 87:1103–1112. https://doi.org/10.1038/labinvest.3700676
Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P, Gelpi E, Giaccone G, Hauw JJ, Hoftberger R et al (2012) Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124:517–529. https://doi.org/10.1007/s00401-012-1002-8
Jackson WS (2014) Selective vulnerability to neurodegenerative disease: the curious case of Prion Protein. Dis Model Mech 7:21–29. https://doi.org/10.1242/dmm.012146
Artikis E, Kraus A, Caughey B (2022) Structural biology of ex vivo mammalian prions. J Biol Chem 298: 102181 https://doi.org/10.1016/j.jbc.2022.102181
Caughey B, Standke HG, Artikis E, Hoyt F, Kraus A (2022) Pathogenic prion structures at high resolution. PLoS Pathog 18:e1010594. https://doi.org/10.1371/journal.ppat.1010594
Rossi M, Baiardi S, Parchi P (2019) Understanding prion strains: evidence from studies of the disease forms affecting humans. Viruses. https://doi.org/10.3390/v11040309
Telling GC (2022) The shape of things to come: structural insights into how prion proteins encipher heritable information. Nat Commun 13:4003. https://doi.org/10.1038/s41467-022-31460-8
Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233
Groveman BR, Foliaki ST, Orru CD, Zanusso G, Carroll JA, Race B, Haigh CL (2019) Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids. Acta Neuropathol Commun 7:90. https://doi.org/10.1186/s40478-019-0742-2
Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA (2013) Cerebral organoids model human brain development and microcephaly. Nature 501:373–379. https://doi.org/10.1038/nature12517
Sun N, Meng X, Liu Y, Song D, Jiang C, Cai J (2021) Applications of brain organoids in neurodevelopment and neurological diseases. J Biomed Sci 28:30. https://doi.org/10.1186/s12929-021-00728-4
Groveman BR, Smith A, Williams K, Haigh CL (2021) Cerebral organoids as a new model for prion disease. PLoS Pathog 17:e1009747. https://doi.org/10.1371/journal.ppat.1009747
Groveman BR, Walters R, Haigh CL (2020) Using our mini-brains: cerebral organoids as an improved cellular model for human prion disease. Neural Regen Res 15:1019–1020. https://doi.org/10.4103/1673-5374.270300
Walters RO, Haigh CL (2022) Organoids for modeling prion diseases. Cell Tissue Res. https://doi.org/10.1007/s00441-022-03589-x
Aguzzi A, Heikenwalder M, Polymenidou M (2007) Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8:552–561. https://doi.org/10.1038/nrm2204
Deleault NR, Piro JR, Walsh DJ, Wang F, Ma J, Geoghegan JC, Supattapone S (2012) Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A 109:8546–8551. https://doi.org/10.1073/pnas.1204498109
Baskakov IV (2014) The many shades of prion strain adaptation. Prion. https://doi.org/10.4161/pri.27836
Block AJ, Bartz JC (2022) Prion strains: shining new light on old concepts. Cell Tissue Res. https://doi.org/10.1007/s00441-022-03665-2
Ritchie DL, Boyle A, McConnell I, Head MW, Ironside JW, Bruce ME (2009) Transmissions of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. J Gen Virol 90:3075–3082. https://doi.org/10.1099/vir.0.013227-0
McNulty E, Nalls AV, Mellentine S, Hughes E, Pulscher L, Hoover EA, Mathiason CK (2019) Comparison of conventional, amplification and bio-assay detection methods for a chronic wasting disease inoculum pool. PLoS ONE 14:e0216621. https://doi.org/10.1371/journal.pone.0216621
Race B, Meade-White KD, Miller MW, Barbian KD, Rubenstein R, LaFauci G, Cervenakova L, Favara C, Gardner D, Long D et al (2009) Susceptibilities of nonhuman primates to chronic wasting disease. Emerg Infect Dis 15:1366–1376. https://doi.org/10.3201/eid1509.090253
Ward A, Hollister JR, McNally K, Ritchie DL, Zanusso G, Priola SA (2020) Transmission characteristics of heterozygous cases of Creutzfeldt-Jakob disease with variable abnormal prion protein allotypes. Acta Neuropathol Commun 8:83. https://doi.org/10.1186/s40478-020-00958-x
Race B, Phillips K, Meade-White K, Striebel J, Chesebro B (2015) Increased infectivity of anchorless mouse scrapie prions in transgenic mice overexpressing human prion protein. J Virol 89:6022–6032. https://doi.org/10.1128/JVI.00362-15
Foliaki ST, Groveman BR, Yuan J, Walters R, Zhang S, Tesar P, Zou W, Haigh CL (2020) Pathogenic prion protein isoforms are not present in cerebral organoids generated from asymptomatic donors carrying the E200K mutation associated with familial prion disease. Pathogens (Basel, Switzerland). https://doi.org/10.3390/pathogens9060482
Groveman BR, Ferreira NC, Foliaki ST, Walters RO, Winkler CW, Race B, Hughson AG, Zanusso G, Haigh CL (2021) Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease. Sci Rep 11:5165. https://doi.org/10.1038/s41598-021-84689-6
Groveman BR, Orru CD, Hughson AG, Bongianni M, Fiorini M, Imperiale D, Ladogana A, Pocchiari M, Zanusso G, Caughey B (2017) Extended and direct evaluation of RT-QuIC assays for Creutzfeldt-Jakob disease diagnosis. Ann Clin Transl Neurol 4:139–144. https://doi.org/10.1002/acn3.378
Orru CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groveman BR, Fiorini M, Pocchiari M, Monaco S, Caughey B et al (2014) A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med 371:519–529. https://doi.org/10.1056/NEJMoa1315200
Race B, Williams K, Chesebro B (2019) Transmission studies of chronic wasting disease to transgenic mice overexpressing human prion protein using the RT-QuIC assay. Vet Res 50:6. https://doi.org/10.1186/s13567-019-0626-2
Manka SW, Zhang W, Wenborn A, Betts J, Joiner S, Saibil HR, Collinge J, Wadsworth JDF (2022) 2.7 A cryo-EM structure of ex vivo RML prion fibrils. Nat Commun 13:4004. https://doi.org/10.1038/s41467-022-30457-7
Hoyt F, Standke HG, Artikis E, Schwartz CL, Hansen B, Li K, Hughson AG, Manca M, Thomas OR, Raymond GJ et al (2022) Cryo-EM structure of anchorless RML prion reveals variations in shared motifs between distinct strains. Nat Commun 13:4005. https://doi.org/10.1038/s41467-022-30458-6
Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial CJD: classification and characterisation. Br Med Bull 66:213–239. https://doi.org/10.1093/bmb/66.1.213
Asante EA, Linehan JM, Desbruslais M, Joiner S, Gowland I, Wood AL, Welch J, Hill AF, Lloyd SE, Wadsworth JD et al (2002) BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 21:6358–6366. https://doi.org/10.1093/emboj/cdf653
Asante EA, Linehan JM, Gowland I, Joiner S, Fox K, Cooper S, Osiguwa O, Gorry M, Welch J, Houghton R et al (2006) Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc Natl Acad Sci U S A 103:10759–10764. https://doi.org/10.1073/pnas.0604292103
Wadsworth JD, Joiner S, Linehan JM, Desbruslais M, Fox K, Cooper S, Cronier S, Asante EA, Mead S, Brandner S et al (2008) Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci U S A 105:3885–3890. https://doi.org/10.1073/pnas.0800190105
Bishop MT, Will RG, Manson JC (2010) Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A 107:12005–12010. https://doi.org/10.1073/pnas.1004688107
Hughson AG, Race B, Kraus A, Sangare LR, Robins L, Groveman BR, Saijo E, Phillips K, Contreras L, Dhaliwal V et al (2016) Inactivation of Prions and Amyloid Seeds with Hypochlorous Acid. PLoS Pathog 12:e1005914. https://doi.org/10.1371/journal.ppat.1005914
Henderson DM, Davenport KA, Haley NJ, Denkers ND, Mathiason CK, Hoover EA (2015) Quantitative assessment of prion infectivity in tissues and body fluids by real-time quaking-induced conversion. J Gen Virol 96:210–219. https://doi.org/10.1099/vir.0.069906-0
Orru CD, Yuan J, Appleby BS, Li B, Li Y, Winner D, Wang Z, Zhan YA, Rodgers M, Rarick J et al (2017) Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aam7785
Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B (2010) Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 6:e1001217. https://doi.org/10.1371/journal.ppat.1001217
Race B, Baune C, Williams K, Striebel JF, Hughson AG, Chesebro B (2022) Second passage experiments of chronic wasting disease in transgenic mice overexpressing human prion protein. Vet Res 53:111. https://doi.org/10.1186/s13567-022-01130-0
Collinge J (2010) Medicine Prion strain mutation and selection. Science 328:1111–1112. https://doi.org/10.1126/science.1190815
Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (2010) Darwinian evolution of prions in cell culture. Science 327:869–872. https://doi.org/10.1126/science.1183218
Gonzalez C, Armijo E, Bravo-Alegria J, Becerra-Calixto A, Mays CE, Soto C (2018) Modeling amyloid beta and tau pathology in human cerebral organoids. Mol Psychiatry 23:2363–2374. https://doi.org/10.1038/s41380-018-0229-8
Matamoros-Angles A, Gayosso LM, Richaud-Patin Y, di Domenico A, Vergara C, Hervera A, Sousa A, Fernández-Borges N, Consiglio A, Gavín R et al (2018) iPS Cell Cultures from a Gerstmann-Sträussler-Scheinker Patient with the Y218N PRNP Mutation Recapitulate tau Pathology. Mol Neurobiol 55:3033–3048. https://doi.org/10.1007/s12035-017-0506-6
Foliaki ST, Schwarz B, Groveman BR, Walters RO, Ferreira NC, Orru CD, Smith A, Wood A, Schmit OM, Freitag P et al (2021) Neuronal excitatory-to-inhibitory balance is altered in cerebral organoid models of genetic neurological diseases. Mol Brain 14:156. https://doi.org/10.1186/s13041-021-00864-w
The authors would like to thank Byron Caughey, Christina Orrú, and James Striebel for critical reading of the manuscript.
Open Access funding provided by the National Institutes of Health (NIH). This research was supported by the Intramural Research Program of the NIH (NIAID).
Ethics approval and consent to participate
Use of mice for the scientific research included in this manuscript was approved by the Institutional Animal Care and Use Committee of the Rocky Mountain Laboratories (RML) protocols 2019–007-E and 2022–006-E. Mouse handling and housing was conducted adhering to the institution’s guidelines for animal use, and followed the guidelines and basic principles in the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals, and the Guide for the Care and Use of Laboratory Animals. Work was carried out by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facility. All human brain tissues used in this study were obtained on autopsy and were therefore exempt from review by the NIH Office of Human Subjects Research Protections.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. Summary of previous results and preparation of organoid inocula. A. Schematic of organoid maturation, inoculation, collection, and inoculation into mice. Cerebral organoids were generated from donor human iPSCs that were heterozygous at codon 129 (MV) as described in Lancaster and Knoblich  and maintained in agitated culture under standard incubator conditions (37˚C, 5% CO2, humidified). Organoids were allowed to mature for 140 days to ensure populations of mature oligodendrocytes and astrocytes were present. Following infection with MV1 and MV2 sCJD brain homogenate inocula, organoids were collected at the indicated time points. Whole organoids from the final time point were homogenized by motorized pestle to 10% w/v in PBS. Homogenates were processed and inoculated into tg66 mice that overexpress human PrPC homozygous for methionine at codon 129 as described in methods. Do = days old, dpi = days post infection. B. Summary of organoid RT-QuIC results showing the loss of detectable seeding activity from the inoculum by 28 dpi and the subsequent re-emergence of de novo, organoid derived, PrPD seeding activity. C. Mass of the organoids from the final collection prior to homogenization to 10% w/v. Organoids used for inocula are indicated by their corresponding letter code. D. Schematic of glycosylation patterns observed in brain and organoid derived PrPC (top) and PrPRes (bottom). Figures modified from .
. Regions and severity of spongiform change consistent between OH and BH inoculated mice for each subtype. Representative H&E staining of different brain regions from mice inoculated with MV-BH or MV-OH homogenates showing the patterns of spongiform change. Brain regions are listed across the top and inocula are listed on the left of the image. Arrows indicate regions of large PrP plaques. Scale bar indicates 50 µm.
. Sub-passaged mice show regions and severity of spongiform change consistent between mice originally inoculated with OH or BH for each subtype. Representative H&E staining of different brain regions from sub-passaged mice inoculated with MV-BH (ms) and MV-OH (ms) homogenates showing the patterns of spongiform change. Arrows indicate regions of large PrP plaques. Inocula are listed on the left of the image. Scale bar indicates 50 µm.
. Brain regions showing statistically significant (p<0.05) differences in lesion scores by Mann-Whitney U test.
About this article
Cite this article
Groveman, B.R., Race, B., Foliaki, S.T. et al. Sporadic Creutzfeldt–Jakob disease infected human cerebral organoids retain the original human brain subtype features following transmission to humanized transgenic mice. acta neuropathol commun 11, 28 (2023). https://doi.org/10.1186/s40478-023-01512-1
- Sporadic CJD
- Cerebral organoid